Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI)

Mild Traumatic Brain Injury Clinical Trial

Official title:

A Randomized Clinical Trial of Quetiapine to Reduce Post Concussive Syndrome Polypharmacy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06333990
• Other study ID #: 20220796HU
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: April 2024
• Est. completion date: March 2028

Study information

• Verified date: March 2024
• Source: Foundation for Advancing Veterans' Health Research
• Contact: Muhammad R Baig, MD
• Phone: 210-617-5300
• Email: muhammad.baig[@]va.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A two site, 2-arm, Phase III randomized pragmatic clinical trial evaluating the effectiveness of quetiapine monotherapy in comparison to Treatment As Usual (TAU) medication management for symptoms experienced by veterans receiving rehabilitation therapy for mild traumatic brain injury (mTBI) and comorbid symptoms of posttraumatic stress disorder (PTSD).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 146
• Est. completion date: March 2028
• Est. primary completion date: March 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Male or female veterans seeking treatment for mTBI, aged 18-65 years

2. Meet mTBI diagnosis and have PCS symptoms reported on the Neurobehavioral Symptom Inventory (NSI). Six months or more must elapse between the injury and Screening. mTBI diagnosis will be determined using the provisional diagnostic convention recommended by the VA/DoD requiring loss of consciousness, or a period of altered consciousness, or posttraumatic amnesia;

3. Be stable (i.e., no dose changes for > 1 month) on at least three CNS active psychotropic medications prescribed for symptom relief or psychiatric treatment.

4. Have posttraumatic symptoms measured by PTSD Checklist for DSM-5 (PCL-5) score =25.

Exclusion Criteria:

1. Moderate or severe TBI, or major neurocognitive disorder (dementia).

2. Meet DSM-5 criteria for schizophrenia, bipolar disorder, schizoaffective disorder, or requiring inpatient hospitalization currently or within past 6 months.

3. Currently taking any antipsychotics or prohibited medication within the past month .

4. Known intolerance to quetiapine or a history of clinically unstable heart, lung, liver, renal, hematological, or endocrinological condition, diabetes mellitus, severe sleep apnea and/or seizure disorder.

5. Substance use disorder severe enough to require medication treatment or medical detoxification or inpatient hospitalization within 6 months of screening.

6. Reporting suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale (CSSRS) in the past 3 months prior to screening or at screening or baseline visit (i.e. active suicidal thought with method and intent but without specific plan, or active suicidal thought with method, intent, and plan); or homicidal ideation with intent or plan to harm others within 90 days or suicide attempt; or suicidal behavior within 6 months prior to screening.

(Note: Study psychiatrist will be immediately notified when SI or HI intent is positive)

7. Current or known history of cardiac arrhythmia or QTc interval = 470 milliseconds.

8. Pregnant or lactating women and those of child-bearing potential not using a reliable method of contraception will be excluded from participating in the study.

Related Conditions & MeSH terms

• Brain Concussion
• Brain Injuries
• Brain Injuries, Traumatic
• Mild Traumatic Brain Injury
• Post-Concussion Syndrome

Intervention

Drug:
• Quetiapine Fumarate
Quetiapine is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia, bipolar disorder, and as an adjunct to treat major depression. It has a broad spectrum of actions at dopaminergic (D1, D2, D3 and D4), serotonergic (5-HT2A, 5-HT2C and 5-HT7), adrenergic (a1), histaminic (H1) and muscarinic (mACh), and partial agonist at 5-HT1A receptors.
• TAU
Standard of care psychotropic medications for treatment of patients with mTBI.

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Foundation for Advancing Veterans' Health Research	Biomedical Research Institute of New Mexico, The University of Texas Health Science Center at San Antonio

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Neurobehavioral Symptom Inventory	A 22- item, self-report measure of symptoms of postconcussive symptoms severity for the preceding 2 week period. Items are scored on a 5-point scale, and a total score is obtained by summing the 22 symptom items, with higher scores indicate greater symptom severity. The total scores range from 0 - 88.	2 weeks
Primary	World Health Organization Disability Assessment Scale	A 12-item, self-report measure of functional disability for the preceding 30 days. Items are scored on a 5-point scale, and a total score is obtained by summing the 12 activities, with higher scores indicate greater disability. The total scores range from 0 - 48.	30 days
Primary	World Health Organization Quality of Life BREF	A 26- item, self-report measure to assess functioning and quality of life for the preceding 2 week period. It is a measure of conceptual domains of quality of life: material and physical well-being, relationships with other people, social, community and civic activities, personal development and fulfillment, independence, and recreation.	2 weeks